

A practical provider guide to helping patients locate Citric Acid/Sodium Citrate in stock. Includes 5 actionable steps, alternatives, and workflow tips.
You've written the prescription. The patient calls back the next day: their pharmacy doesn't have it, the next pharmacy doesn't have it, and they're running low. Citric Acid/Sodium Citrate (Bicitra, Cytra-2, Oracit) is a medication that works well when patients can get it — but availability gaps can create real barriers to adherence.
This guide provides practical, actionable steps your practice can take to help patients maintain access to Citric Acid/Sodium Citrate, along with clinical alternatives and workflow optimizations.
Citric Acid/Sodium Citrate is not in an official FDA-recognized shortage as of early 2026, but it has a history of intermittent supply disruptions. The key factors driving availability challenges include:
The result is a medication that's available in the supply chain but often not on pharmacy shelves — an important distinction that informs the solutions below.
From the patient perspective, the barriers compound:
This process often takes days, during which the patient may be going without a medication they need for kidney stone prevention, metabolic acidosis, or gout management.
Before sending the prescription electronically, take 60 seconds to check if the patient's preferred pharmacy has Citric Acid/Sodium Citrate in stock. Medfinder for Providers offers real-time availability data that can prevent fill failures before they happen.
If the patient's usual pharmacy doesn't carry it, you can route the prescription to one that does — saving the patient a frustrating runaround.
Consider including a note on the prescription that allows for therapeutic substitution in case of unavailability. For example:
"If Sodium Citrate/Citric Acid oral solution is unavailable, may substitute Potassium Citrate oral solution at equivalent dose — contact prescriber to confirm."
This gives the pharmacist a pathway to help the patient without requiring a new prescription and a callback loop. Be aware that substitution rules vary by state, and some pharmacies may still require explicit authorization.
When chain pharmacies can't fill the prescription, direct patients toward:
If the patient's insurance allows it, prescribing a 90-day supply reduces the frequency of refills and, consequently, the number of opportunities for fill failures. This is a simple change that can meaningfully reduce patient burden.
For patients on chronic Citric Acid/Sodium Citrate therapy, document a backup medication in the chart. If the primary medication becomes unavailable, the backup can be prescribed quickly without requiring a full reassessment. Common backups include:
When Citric Acid/Sodium Citrate is not available, the following alternatives may be appropriate depending on the patient's clinical profile:
For a detailed comparison, see: Alternatives to Citric Acid/Sodium Citrate.
Incorporating a few simple steps into your clinical workflow can significantly reduce Citric Acid/Sodium Citrate fill failures:
The availability challenges with Citric Acid/Sodium Citrate are manageable but require proactive planning. By verifying availability before prescribing, maintaining backup medication plans, and leveraging tools like Medfinder for Providers, your practice can help patients avoid unnecessary disruptions in their treatment.
For a broader overview of the supply situation, see our provider shortage briefing for Citric Acid/Sodium Citrate. For patient cost and savings resources, see our guide on how to help patients save money on Citric Acid/Sodium Citrate.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.